Indication
Amyotrophic lateral sclerosis with superoxide dismutase gene mutation
Amyotrophic lateral sclerosis with superoxide dismutase gene mutation (SOD1-ALS) is a rare, genetically defined subtype of amyotrophic lateral sclerosis characterized by mutations in the *SOD1* gene, which accounts for approximately 10% to 20% of familial cases and a small fraction of sporadic disease. Read more about Amyotrophic lateral sclerosis with superoxide dismutase gene mutation
1 drugs 1 manufacturers
Drugs that treat it
Common Amyotrophic lateral sclerosis with superoxide dismutase gene mutation therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAmyotrophic lateral sclerosis with superoxide dismutase gene mutation (SOD1-ALS) is a rare, genetically defined subtype of amyotrophic lateral sclerosis characterized by mutations in the *SOD1* gene, which accounts for approximately 10% to 20% of familial cases and a small fraction of sporadic disease.
This progressive neurodegenerative disorder targets both upper and lower motor neurons within the motor cortex, brainstem, and spinal cord.
Pathophysiologically, pathogenic variants promote the misfolding, toxic accumulation, and aggregation of superoxide dismutase protein, triggering neuroinflammation, axonal degeneration, and motor neuron apoptosis.
Clinically, affected individuals present with relentless muscle weakness, fasciculations, muscle atrophy, spasticity, and eventual paralysis, which progressively impairs mobility, speech, swallowing, and respiratory function.
- nih.gov
Amyotrophic lateral sclerosis with superoxide dismutase gene mutation (SOD1-ALS) is a rare, genetically defined subtype of amyotrophic lateral sclerosis characterized by mutations in the *SOD1* gene, which accounts for approximately 10% to 20% of familial cases and a small fraction of sporadic disease
- fda.gov
Amyotrophic lateral sclerosis with superoxide dismutase gene mutation (SOD1-ALS) is a rare, genetically defined subtype of amyotrophic lateral sclerosis characterized by mutations in the *SOD1* gene, which accounts for approximately 10% to 20% of familial cases and a small fraction of sporadic disease Pathophysiologically, pathogenic variants promote the misfolding, toxic accumulation, and aggregation of superoxide dismutase protein, triggering neuroinflammation, axonal degeneration, and motor n...
- pharmacytimes.com
This progressive neurodegenerative disorder targets both upper and lower motor neurons within the motor cortex, brainstem, and spinal cord
- nih.gov
This progressive neurodegenerative disorder targets both upper and lower motor neurons within the motor cortex, brainstem, and spinal cord
- medlineplus.gov
Pathophysiologically, pathogenic variants promote the misfolding, toxic accumulation, and aggregation of superoxide dismutase protein, triggering neuroinflammation, axonal degeneration, and motor neuron apoptosis
- nih.gov
Pathophysiologically, pathogenic variants promote the misfolding, toxic accumulation, and aggregation of superoxide dismutase protein, triggering neuroinflammation, axonal degeneration, and motor neuron apoptosis
- medlineplus.gov
Clinically, affected individuals present with relentless muscle weakness, fasciculations, muscle atrophy, spasticity, and eventual paralysis, which progressively impairs mobility, speech, swallowing, and respiratory function
Personalize your experience
Follow Amyotrophic lateral sclerosis with superoxide dismutase gene mutation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.